Annals of Hematology

, Volume 83, Issue 4, pp 201–205 | Cite as

Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects

  • Nicola GökbugetEmail author
  • Dieter Hoelzer
Review Article


After rapid improvement of treatment results in adult acute lymphoblastic leukemia (ALL) from less than 10% to 30–40% in the past decades, more recently stagnation has been observed. In addition, a borderline for further intensification of chemotherapy appears to be reached in adult ALL patients. New, preferably non-chemotherapy, approaches are therefore urgently required. One of those is targeted therapy with monoclonal antibodies (MoAbs). ALL blast cells express a variety of specific antigens which may serve as targets, such as CD19, CD20, CD22, CD33, and CD52. Published results of MoAbs in ALL are reviewed. Most experience is available for anti-CD20 (rituximab) which led to a significant improvement of the outcome in B-cell non-Hodgkin’s lymphoma (NHL). In ALL, rituximab is combined with chemotherapy mainly in mature B-ALL and Burkitt’s lymphoma and preliminary results are promising. In the future, studies will also be done in B-precursor ALL. Another promising B-cell antibody is anti-CD22. Several CD19 MoAbs were also tested in phase I studies. However, results are not conclusive and these MoAbs are not generally available. Far less experience with MoAb therapy is available for T-ALL, but clinical studies are on the way with anti-CD52 and anti-CD25 in adult T-cell leukemia/lymphoma. Overall, it can be stated that MoAb therapy in ALL is a promising treatment approach. Monotherapy with MoAbs in relapsed ALL occasionally led to responses, but higher effectivity can be expected from a combination with chemotherapy and treatment in the state of minimal residual disease. Well-designed studies and joint efforts are required to explore optimal combinations, timing and dosage of MoAb therapy in ALL.


Acute Lymphoblastic leukemia Antibodies Therapy Relapse 


  1. 1.
    Hoelzer D, Gökbuget N (2000) New approaches in acute lymphoblastic leukemia in adults: Where do we go? Semin Oncol 27:540–559PubMedGoogle Scholar
  2. 2.
    Tallman MS (2002) Monoclonal antibody therapies in leukemias. Semin Hematol 39:12–19CrossRefPubMedGoogle Scholar
  3. 3.
    Faderl S, Kantarjian HM, O’Brien S, et al (2000) A broad exploratory trial of Campath-1H in the treatment of acute leukemias. Blood 96:1397aGoogle Scholar
  4. 4.
    Thomas DA, Cortes J, Giles FJ, et al (2002) Rituximab and hyper-CVAD for adult Burkitt’s (BL) or Burkitt’s-like (BLL) leukemia or lymphoma. Blood 100:3022Google Scholar
  5. 5.
    Ozsahin H, Fluss J, McLin V, Wacker P (2003) Rituximab with interleukin-2 after autologous bone marrow transplantation for acute lymphocytic leukemia in second remission. Med Pediatr Oncol 38:300–301CrossRefGoogle Scholar
  6. 6.
    Jandula BM, Nomdedeu J, Marin P, Vivancos P (2001) Rituximab can be useful as treatment for minimal residual disease in bcr-abl-positive acute lymphoblastic leukemia. Bone Marrow Transplant 27:225–227CrossRefPubMedGoogle Scholar
  7. 7.
    Chen CL, Levine A, Rao A, et al (1999) Clinical pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-Genistein in patients with B-lineage lymphoid malignancies. J Clin Pharmacol 39:1248–1255CrossRefPubMedGoogle Scholar
  8. 8.
    Uckun FM, Nachman JB, Sather HN, et al (1999) Poor treatment outcome of Philadelphia chromosome-positive pediatric acute lymphoblastic leukemia despite intensive chemotherapy. Leuk Lymphoma 33:101–106PubMedGoogle Scholar
  9. 9.
    Seibel NL, Krailo M, O’Neill K, Franklin J, Uckun F, Reaman GH (1998) Phase I study of B43-PAP immunotoxin in combination with standard 4-drug induction for patients with CD19+ acute lymphoblastic leukemia (ALL) in relapse. A Children’s Cancer Group Study. Blood 92:1651Google Scholar
  10. 10.
    Szatrowski TP, Dodge RK, Reynolds C, et al (2003) Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine. Cancer 97:1471–1480CrossRefPubMedGoogle Scholar
  11. 11.
    Dinndorf P, Krailo M, Liu-Mares W, Frierdich S, Sondel P, Reaman G (2001) Phase I trial of anti-B4-blocked ricin in pediatric patients with leukemia and lymphoma. J Immunother 24:511–516CrossRefPubMedGoogle Scholar
  12. 12.
    Herrera L, Farah RA, Pellegrini VA, et al (2000) Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia 14:853–858CrossRefPubMedGoogle Scholar
  13. 13.
    Herrera L, Yarbrough S, Ghetie V, Aquino DB, Vitetta ES (2003) Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins. Leukemia 17:334–338CrossRefPubMedGoogle Scholar
  14. 14.
    Lew G, Gu L, Zhou M, et al (2002) BL22, an Anti-CD22 recombinant immunotoxin, is active in vitro and in vivo against B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cells from pediatric patients. Blood 100:3024 (abstract)Google Scholar
  15. 15.
    Kolitz JE, O’Mara V, Willemze R, et al (1994) Treatment of acute lymphoblastic leukemia (ALL) with Campath-1H: Initial observations. Blood 84:1191aGoogle Scholar
  16. 16.
    Massenkeil G, Rackwitz S, Genvresse I, Rosen O, Dorken B, Arnold R (2002) Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant 30:899–903CrossRefPubMedGoogle Scholar
  17. 17.
    Kode R, Fa K, Chowdhury S, et al (2003) Basiliximab plus low-dose cyclosporin vs OKT3 for induction immunosuppression following renal transplantation. Clin Transplant 17:369–76CrossRefPubMedGoogle Scholar
  18. 18.
    Waldmann TA, White JD, Goldman CK, et al (1993) The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood 82:1701–1712PubMedGoogle Scholar
  19. 19.
    Seibel NL, Sather H, Steinherz PG, et al (2000) Upfront treatment with B43 PAP immunotoxin in newly diagnosed children with higher risk ALL—Children’s Cancer Group 1961. Blood 96:3115aGoogle Scholar
  20. 20.
    Kolitz JE, O’Mara V, Willemze R, et al (1994) Treatment of acute lymphoblastic leukemia (ALL) with Campath-1H: initial observations. Blood 84 (Suppl 1):301aGoogle Scholar
  21. 21.
    Zwaan C, Reinhardt D, Jurgens H, et al (2003) Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin. Leukemia 17:468–470CrossRefPubMedGoogle Scholar
  22. 22.
    Vallera DA, Burns LJ, Frankel AE, et al (1996) Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T-cell malignancies. J Immunol Methods 197:69–83CrossRefPubMedGoogle Scholar
  23. 23.
    Waurzyniak BJ, Schneider EA, Tumer N, et al (1997) In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin. Clin Cancer Res 3:881–890Google Scholar
  24. 24.
    Zhang Z, Zhang M, Ravetch JV, Goldman C, Waldmann TA (2003) Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. Blood (prepublished online Mar 20)Google Scholar
  25. 25.
    Gramatzki M, Burger R, strobel G, et al (1995) Therapy with OKT3 monoclonal antibody in refractory T-cell acute lymphoblastic leukemia induces interleukin-2 responsiveness. Leukemia 9:390Google Scholar
  26. 26.
    Frankel AE, Laver JH, Willingham MC, Burns LJ, Kersey JH, Vallera DA (1997) Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin. Leuk Lymphoma 26:287–298PubMedGoogle Scholar
  27. 27.
    Carpenter PA, Appelbaum FR, Corey L, et al (2002) A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 99:2712–2719CrossRefPubMedGoogle Scholar
  28. 28.
    Cheson BD (2003) Radioimmunotherapy of non-Hodgkin lymphomas. Blood 101:391–398CrossRefPubMedGoogle Scholar
  29. 29.
    Bunjes D, Duncker C, Seitz U, et al (1998) Intensification of the conditioning regimen for high-risk leukaemia with a 188Re- labelled anti-CD 164b monoclonal antibody: results of feasibility study. Blood 92:4471aGoogle Scholar
  30. 30.
    Matthews DC, Appelbaum FR, Eary JF, et al (1999) Phase I study of 131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 94:1237–1247PubMedGoogle Scholar
  31. 31.
    Bunjes D, Buchmann I, Duncker C, et al (2001) Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. Blood 98:565–572PubMedGoogle Scholar
  32. 32.
    Klein SA, Hermann S, Dietrich JW, Hoelzer D, Martin H (2002) Transplantation-related toxicity and acute intestinal graft-versus-host disease after conditioning regimens intensified with rhenium 188-labeled anti-CD66 monoclonal antibodies. Blood 99:2270–2271CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  1. 1.Medical Clinic IIIUniversity HospitalFrankfurtGermany

Personalised recommendations